Positive results from the phase 3 PRIME2 trial – part of the LIBERTY-PN PRIME clinical programme – assessing the safety and effectiveness of Sanofi and Regeron’s Dupixent (dupilumab) were shared at the American Academy of Dermatology (AAD) 2022 Annual Meeting.

21 scientific abstracts in total were presented at the Congress, which assessed the safety and effectiveness of Dupixent for patients with atopic dermatitis in various age groups, as well as investigational indications, prurigo nodularis and chronic spontaneous urticaria.

Prurigo nodularis produces an intense and persistent itch in patients diagnosed with the condition, with thick skin lesions, called nodules, that can cover the body. Topical steroids are typically prescribed, but are associated with safety risks when used long term.

The PRIME2 trial, a randomised, placebo-controlled study, met primary and all key secondary endpoints. It demonstrated that 37% of Dupixent patients experienced a clinically meaningful itch reduction from baseline, compared to 22% of placebo patients at week 12, the primary endpoint, while almost three times as many Dupixent patients experienced a clinically meaningful reduction in itch from baseline at week 24.

Almost three times as many Dupixent patients (45%) had clear or almost clear skin at week 24, compared to 16% of placebo patients.